A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

• Main Authors: Hua Zhang (Author), Shu Yan (Author), Yan Zhan (Author), Sheng Ma (Author), Yicong Bian (Author), Shaorong Li (Author), Junjun Tian (Author), Guangze Li (Author), Dafang Zhong (Author), Xingxing Diao (Author), Liyan Miao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

SHR6390 (dalpiciclib) is a selective and effective cyclin-dependent kinase (CDK) 4/6 inhibitor and an effective cancer therapeutic agent. On 31 December 2021, the new drug application was approved by National Medical Product Administration (NMPA). The metabolism, mass balance, and pharmacokinetics o...